Itolizumab
Product Sizes
5 mg
£ POA
HY-P99252-5MG
10 mg
£ POA
HY-P99252-10MG
1 mg
£ POA
HY-P99252-1MG
About this Product
- SKU:
- HY-P99252
- Additional Names:
- Anti-Human CD6 Recombinant Antibody
- CAS Number:
- 1116433-11-4
- Extra Details:
- Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines; such as INF-γ; TNFα and IL-6. Itolizumab can be used in the research of psoriasis; rheumatoid arthritis (RA); COVID-19[1][2][3].
- Molecular Weight:
- (146.66 kDa)
- Purity:
- 99.0
- References:
- [1]Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. |[2]Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. |[3]Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. |[4]Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. |[5]Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688. |[6]Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088. |[7]Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.
- Research Area:
- Infection; Inflammation/Immunology
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- Store at -80[o]C for 2 years
- Type:
- Antibodies
- Pathway:
- Immunology/Inflammation
